215 related articles for article (PubMed ID: 36789095)
1. Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review.
Donnez J; Cacciottola L; Squifflet JL; Dolmans MM
Drug Des Devel Ther; 2023; 17():369-380. PubMed ID: 36789095
[TBL] [Abstract][Full Text] [Related]
2. GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis?
Donnez J; Dolmans MM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768770
[TBL] [Abstract][Full Text] [Related]
3. Linzagolix: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1317-1325. PubMed ID: 35997940
[TBL] [Abstract][Full Text] [Related]
4. Update on the management of endometriosis-associated pain in France.
Fernandez H; Agostini A; Baffet H; Chabbert-Buffet N; Descamps P; Estrade JP; Giraudet G; Hocke C; Salle B; Tremollieres F; Chapron C
J Gynecol Obstet Hum Reprod; 2023 Nov; 52(9):102664. PubMed ID: 37669732
[TBL] [Abstract][Full Text] [Related]
5. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats.
Tezuka M; Tsuchioka K; Kobayashi K; Kuramochi Y; Kiguchi S
Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):610-617. PubMed ID: 37186405
[TBL] [Abstract][Full Text] [Related]
6. Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review.
Donnez J; Dolmans MM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33807739
[TBL] [Abstract][Full Text] [Related]
7. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
[TBL] [Abstract][Full Text] [Related]
8. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.
Yan H; Shi J; Li X; Dai Y; Wu Y; Zhang J; Gu Z; Zhang C; Leng J
Fertil Steril; 2022 Dec; 118(6):1102-1116. PubMed ID: 36283862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
Tezuka M; Tamai Y; Kuramochi Y; Kobayashi K; Fushimi N; Kiguchi S
Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1082-1093. PubMed ID: 35690889
[TBL] [Abstract][Full Text] [Related]
10. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
11. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Dababou S; Garzon S; Laganà AS; Ferrero S; Evangelisti G; Noventa M; D'Alterio MN; Palomba S; Uccella S; Franchi M; Barra F
Expert Opin Investig Drugs; 2021 Sep; 30(9):903-911. PubMed ID: 34278887
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis.
Xin L; Ma Y; Ye M; Chen L; Liu F; Hou Q
Arch Gynecol Obstet; 2023 Oct; 308(4):1047-1056. PubMed ID: 36656435
[TBL] [Abstract][Full Text] [Related]
13. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
Kim SM; Yoo T; Lee SY; Kim EJ; Lee SM; Lee MH; Han MY; Jung SH; Choi JH; Ryu KH; Kim HT
Life Sci; 2015 Oct; 139():166-74. PubMed ID: 26321528
[TBL] [Abstract][Full Text] [Related]
14. A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.
Pohl O; Baron K; Riggs M; French J; Garcia R; Gotteland JP
Br J Clin Pharmacol; 2022 May; 88(5):2359-2371. PubMed ID: 34904270
[TBL] [Abstract][Full Text] [Related]
15. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
[TBL] [Abstract][Full Text] [Related]
16. Pituitary effects of steroid hormones on secretion of follicle-stimulating hormone and luteinizing hormone.
Nett TM; Turzillo AM; Baratta M; Rispoli LA
Domest Anim Endocrinol; 2002 Jul; 23(1-2):33-42. PubMed ID: 12142224
[TBL] [Abstract][Full Text] [Related]
17. Novel pharmacological therapies for the treatment of endometriosis.
Buggio L; Dridi D; Barbara G; Merli CEM; Cetera GE; Vercellini P
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1039-1052. PubMed ID: 36000243
[TBL] [Abstract][Full Text] [Related]
18. The effect of sex steroids on pituitary responsiveness to gonadotropin releasing hormone.
Eshkol A; Lunenfeld B; Insler V
J Steroid Biochem; 1975 Jun; 6(6):1061-6. PubMed ID: 1100906
[TBL] [Abstract][Full Text] [Related]
19. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacotherapy for treating endometriosis.
Tafi E; Leone Roberti Maggiore U; Alessandri F; Bogliolo S; Gardella B; Vellone VG; Grillo F; Mastracci L; Ferrero S
Expert Opin Pharmacother; 2015; 16(16):2465-83. PubMed ID: 26569155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
